Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Sarcoma, Alveolar Soft Part 1Neuroendocrine Tumors 1Metastatic Neuroendocrine Prostate Cancer 1Chondrosarcoma 1Advanced Solid Tumors 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × Antiemetics × Clear all
NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡